The next generation of biotech blockbusters

The 2007 rate of new biologic approvals was slow, with only a handful of drugs squeaking through FDA review. But the pace is set to pick up in 2008. According to IMS Health, several biologics could receive FDA approval this year if they don't hit any stumbling blocks. Each of the drugs on this list has the potential for over a billion dollars in sales if all goes according to plan. The next generation of biologic blockbusters that could offer real breakthroughs for patients--and add significant cash to their developers' bottom lines. List

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.